Dealing room buzz: Sun Pharma, RInfra, Ranbaxy and Bharti

MUMBAI: ET Now spoke to dealers on institutional and high net worth investors’ activity in the dealing room.

The following stocks were on their radar on unconfirmed reports:-

Sun Pharmaceuticals: The stock is expected to be under pressure after the company’s subsidiary Taro lost market share in Nystatin, say dealers.

According to Citigroup report, Product pipeline of Taro is not sufficient to offset competition. Taro’s market share in Topicort may also come down following FDA approval for Glenmark for generic version.

Reliance Infrastructure: Desks indicate HNI selling likely in second half of the session.

The stock was at Rs 410.60, up 0.43 per cent, on the BSE. It touched a high of Rs 415.55 and a low of Rs 401.45 in trade today.

Ranbaxy Laboratories: Dealers suggest accumulating the stock on dips.

The stock was at Rs 334.90, down 0.43 per cent, on the BSE. It touched a high of Rs 341.80 and a low of Rs 331.70 in trade today.

Bharti Airtel: Dealers suggest selling the stock at higher levels. Dollar denominated debt remains a concern, say analysts.

The stock was at Rs 329.80, down 1.57 per cent, on the BSE. It touched a high of Rs 335.80 and a low of Rs 328.50 in trade today.

Glenmark Pharmaceuticals: Dealers suggest buying the stock at lower levels. They expect the recent ANDA approvals to drive growth.

The stock was at Rs 500, up 1.05 per cent, on the BSE. It touched a high of Rs 508.35 and a low of Rs 492.70 in trade today.



Disclaimer: The above report is based on market buzz and information given by dealers. Please consult your financial advisor before taking any position in the stocks mentioned.